Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Magenta Therapeutics, Inc. (MGTA) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights"
05/16/2022 8-K Quarterly results
03/08/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights",
"Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology Annual Meeting"
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/03/2020 8-K Quarterly results
11/13/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "Magenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights"
05/09/2019 8-K Quarterly results
Docs: "Magenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights"
11/08/2018 8-K Quarterly results
Docs: "Magenta Therapeutics, Inc. STATEMENTS OF OPERATIONS Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Revenue $ — $ — $ — $ — Operating expenses: Research and development 11,418 5,210 28,950 22,348 General and administrative 5,284 1,805 13,083 5,209 Total operating expenses 16,702 7,015 42,033 27,557 Loss from operations Interest and other income, net 687 102 1,197 102 Net loss Accretion of redeemable convertible preferred stock to redemption value — Cumulative dividends on redeemable convertible preferred stock — — — Reversal of cumulative dividends on redeemable convertible preferred stock — — — 634 Net loss attributable to common stockholders $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted averag..."
08/09/2018 8-K Quarterly results
Docs: "Magenta Therapeutics, Inc. STATEMENTS OF OPERATIONS Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Revenue $ — $ — $ — $ — Operating expenses: Research and development 9,683 13,816 17,532 17,138 General and administrative 4,342 1,915 7,799 3,404 Total operating expenses 14,025 15,731 25,331 20,542 Loss from operations Interest and other income, net 365 — 510 — Net loss Accretion of redeemable convertible preferred stock to redemption value Cumulative dividends on redeemable convertible preferred stock — — Reversal of cumulative dividends on redeemable convertible preferred stock — 634 — 634 Net loss attributable to common stockholders $ $ $ $ Net loss per share attributable to common stockholders—basic and diluted $ $ $ $ Weighted average common shares out..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy